EP1212065A4 - Compositions et methodes permettant d'augmenter les taux de hdl cholesterol - Google Patents

Compositions et methodes permettant d'augmenter les taux de hdl cholesterol

Info

Publication number
EP1212065A4
EP1212065A4 EP00947080A EP00947080A EP1212065A4 EP 1212065 A4 EP1212065 A4 EP 1212065A4 EP 00947080 A EP00947080 A EP 00947080A EP 00947080 A EP00947080 A EP 00947080A EP 1212065 A4 EP1212065 A4 EP 1212065A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
cholesterol levels
hdl cholesterol
raising hdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00947080A
Other languages
German (de)
English (en)
Other versions
EP1212065A1 (fr
Inventor
Bei Shan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of EP1212065A1 publication Critical patent/EP1212065A1/fr
Publication of EP1212065A4 publication Critical patent/EP1212065A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00947080A 1999-07-08 2000-07-07 Compositions et methodes permettant d'augmenter les taux de hdl cholesterol Withdrawn EP1212065A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US612135 1990-11-13
US14299499P 1999-07-08 1999-07-08
US142994P 1999-07-08
US61213500A 2000-07-07 2000-07-07
PCT/US2000/018533 WO2001003705A1 (fr) 1999-07-08 2000-07-07 Compositions et methodes permettant d'augmenter les taux de hdl cholesterol

Publications (2)

Publication Number Publication Date
EP1212065A1 EP1212065A1 (fr) 2002-06-12
EP1212065A4 true EP1212065A4 (fr) 2004-02-11

Family

ID=26840588

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00947080A Withdrawn EP1212065A4 (fr) 1999-07-08 2000-07-07 Compositions et methodes permettant d'augmenter les taux de hdl cholesterol

Country Status (5)

Country Link
EP (1) EP1212065A4 (fr)
JP (1) JP2004500332A (fr)
AU (1) AU6074700A (fr)
CA (1) CA2377999A1 (fr)
WO (1) WO2001003705A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
JP2003520780A (ja) * 1999-09-01 2003-07-08 ユニバーシティ オブ ブリティッシュ コロンビア Ｈｄｌコレステロールとトリグリセリド水準を調節する組成物と方法
AU2001262984A1 (en) * 2000-05-03 2001-11-12 Tularik, Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
AU2002236830A1 (en) * 2001-01-26 2002-08-06 Chugai Seiyaku Kabushiki Kaisha Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
WO2002064136A2 (fr) * 2001-01-26 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de malonyl-coa decarboxylase utiles en tant que modulateurs metaboliques
ES2362270T3 (es) * 2001-01-26 2011-06-30 Chugai Seiyaku Kabushiki Kaisha Inhibidores de malonil-coa decarboxilasa útiles como moduladores metabólicos.
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
CA2437409C (fr) 2001-02-20 2010-10-19 Chugai Seiyaku Kabushiki Kaisha Azoles en inhibiteurs de la decarboxylase des malonyl-coa, convenant comme modulateurs metaboliques
WO2002077229A2 (fr) * 2001-03-01 2002-10-03 Lion Bioscience Ag Nouveaux cofacteurs du recepteur alpha x du foie et techniques d'utilisation
EP1379259A1 (fr) 2001-04-18 2004-01-14 Genzyme Corporation Methodes pour traiter le syndrome x avec des polyamines aliphatiques
EP1285662A1 (fr) * 2001-08-20 2003-02-26 ZLB Bioplasma AG Lipoprotéine à haute densité reconstituée utilisée pour le traitement d' attaques et des conditions d'ischémie
CA2457840C (fr) 2001-08-20 2011-10-11 Zlb Bioplasma Ag Lipoproteines de haute densite (hdl) pour le traitement des accidents vasculaires cerebraux (avc) et autres evenements ischemiques
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
GB2381866A (en) * 2001-11-12 2003-05-14 Karobio Ab Assays for liver X receptor (LXR) modulators
WO2003059884A1 (fr) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulateurs de lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US20050171084A1 (en) * 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
WO2003090869A1 (fr) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Modulateurs de lxr
WO2003090732A1 (fr) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Modulateurs lxr pour le traitement des maladies cardio-vasculaires
GB0316237D0 (en) * 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) * 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US20060189693A1 (en) * 2003-07-22 2006-08-24 Barone Frank C Methods of treatment with lxr agonists
US7285562B2 (en) 2003-08-01 2007-10-23 Chugai Seiyaku Kabushiki Kaisha Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors
CA2533749C (fr) 2003-08-01 2012-07-10 Chugai Seiyaku Kabushiki Kaisha Composes de piperidine utiles en tant qu'inhibiteurs de malonyl-coa decarboxylase
CA2533747C (fr) 2003-08-01 2012-11-13 Chugai Seiyaku Kabushiki Kaisha Composes heterocycliques utiles comme inhibiteurs de la malonyl-coa decarboxylase
US7786145B2 (en) 2003-08-01 2010-08-31 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-CoA decarboxylase inhibitors
WO2006073364A1 (fr) * 2005-01-10 2006-07-13 Astrazeneca Ab Derives non aniliques d'isothiazol-3(2h)-thione 1,1-dioxides servant de modulateurs de recepteurs nucleaires hepatiques
CA2592771A1 (fr) * 2005-01-10 2006-07-13 Astrazeneca Ab Derives de 1,1-dioxydes d'isothiazol-3(2h)-one utilises comme modulateurs du recepteur x du foie
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500056D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
US8703805B2 (en) 2005-06-27 2014-04-22 Exelixis Patent Company Llc Modulators of LXR
AU2006272922A1 (en) 2005-07-22 2007-02-01 Amgen Inc. Aniline sulfonamide derivatives and their uses
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
CN105250253B (zh) * 2015-10-30 2018-06-26 黄恺 T0901317作为parp1抑制剂的应用
CN109071516B (zh) 2015-12-15 2021-08-31 阿斯利康(瑞典)有限公司 新颖的化合物
JP2020524660A (ja) 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034461A2 (fr) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions et techniques de modulation du metabolisme du cholesterol
WO2000054759A2 (fr) * 1999-03-15 2000-09-21 Tularik Inc. Modulateurs du lxr
WO2000078972A2 (fr) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Compositions et procedes visant a augmenter la sortie de cholesterol et a augmenter la hdl au moyen de la proteine de transport de cassettes de liaison d'atp abc1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES442992A1 (es) * 1974-12-02 1977-08-01 Scherico Ltd Un procedimiento para preparar 2-anilino-oxazolinas.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034461A2 (fr) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions et techniques de modulation du metabolisme du cholesterol
WO2000054759A2 (fr) * 1999-03-15 2000-09-21 Tularik Inc. Modulateurs du lxr
WO2000078972A2 (fr) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Compositions et procedes visant a augmenter la sortie de cholesterol et a augmenter la hdl au moyen de la proteine de transport de cassettes de liaison d'atp abc1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO0103705A1 *
YOUNG S G ET AL: "THE ABCS OF CHOLESTEROL EFFLUX", NATURE GENETICS, NEW YORK, NY, US, vol. 22, no. 4, August 1999 (1999-08-01), pages 316 - 318, XP000889764, ISSN: 1061-4036 *

Also Published As

Publication number Publication date
WO2001003705A1 (fr) 2001-01-18
EP1212065A1 (fr) 2002-06-12
JP2004500332A (ja) 2004-01-08
AU6074700A (en) 2001-01-30
CA2377999A1 (fr) 2001-01-18

Similar Documents

Publication Publication Date Title
EP1212065A4 (fr) Compositions et methodes permettant d'augmenter les taux de hdl cholesterol
NZ514350A (en) Compositions and methods for effecting the levels of cholesterol
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
EP1176948A4 (fr) Compositions et methodes antinauseeuses
GB0121314D0 (en) β-Secretase enzyme compositions and methods
AUPQ419099A0 (en) Novel compositions and methods
GB2348808B (en) Methods and compositions for desensitisation
GB9920678D0 (en) Sanitising compositions and methods
AU3877900A (en) Compositions and methods for preventing and treating sexual dysfunctions
AU4215901A (en) Methods and compositions for immunoregulation
IL139386A0 (en) Dhea composition and method
AU6094200A (en) Nor gene compositions and methods for use thereof
AU2001261513A1 (en) Composition and method for increasing testosterone levels
AU5474400A (en) Compositions and methods for targeted gene insertion
EP1238095A4 (fr) Compositions et methodes d'apoptose induite par caspase
EP1207896A4 (fr) Procedes et compositions servant a limiter les niveaux de phosphate serique
AU2003257051A8 (en) Composition and method for lowering cholesterol
GB0318107D0 (en) ›-Secretase enzyme compositions and methods
AU1477601A (en) Genetic compositions and methods
AU5931300A (en) Ringene compositions and methods for use thereof
AU1623801A (en) Opioid metallopeptide compositions and methods
HUP0100613A3 (en) Methods and compositions for stabilizing acetylcholine compositions
AU3347300A (en) Desmethylsildenafil compositions and methods
GB9928549D0 (en) Compositions and methods
GB9916503D0 (en) Compositions and methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020112;LT PAYMENT 20020112;LV PAYMENT 20020112;MK PAYMENT 20020112;RO PAYMENT 20020112;SI PAYMENT 20020112

A4 Supplementary search report drawn up and despatched

Effective date: 20040102

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 3/06 B

Ipc: 7A 61K 31/18 A

17Q First examination report despatched

Effective date: 20040423

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060201